---
schema_version: "secwatch.filing_event.v1"
accession: "0001367644-23-000082"
form_type: "8-K"
ticker: "EBS"
cik: "0001367644"
company_name: "Emergent BioSolutions Inc."
filed_at: "2023-04-17T23:59:59+00:00"
generated_at: "2026-06-17T01:15:59.893285+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Emergent BioSolutions extends limited waiver of credit covenant compliance through May 17, 2023

## Summary
- Entered into Waiver Amendment to Credit Agreement Amendment dated February 14, 2023, with lenders led by Wells Fargo.
- Extended Limited Waiver covers defaults from financial covenant violations for fiscal quarters ending Dec 31, 2022 and Mar 31, 2023.
- Waiver also addresses going concern qualification in audited financial statements for fiscal year ending December 31, 2022.
- Company is working with lenders to replace current credit facility and extend the October 2023 maturity.
- Company previously announced sale of travel health business to Bavarian Nordic for up to $380 million.

## SEC filing metadata
- accession: 0001367644-23-000082
- form_type: 8-K
- ticker: EBS
- cik: 0001367644
- company_name: Emergent BioSolutions Inc.
- filed_at: 2023-04-17T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1367644/000136764423000082/0001367644-23-000082-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1367644/000136764423000082/ebs-20230417.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001367644-23-000082
- JSON: https://secwatch.observer/filing/0001367644-23-000082.json
- Plain text: https://secwatch.observer/filing/0001367644-23-000082.txt

## Key facts
- Material Agreements
  Emergent BioSolutions Inc. amended First Amendment to the Consent, Limited Waiver, and Third Amendment to the Amended and Restated Credit Agreement with Wells Fargo Bank, National Association, as administrative agent, and certain lenders valued at Extended Limited Waiver of defaults or events of default resulting from violation of financial coven (effective 2023-04-17).
  - Action: amendment
  - Agreement: credit facility
  - Counterparty: Wells Fargo Bank, National Association, as administrative agent, and certain lenders
  - Value: Extended Limited Waiver of defaults or events of default resulting from violation of financial coven
  - Effective: 2023-04-17
  source text: On April 17, 2023, Emergent BioSolutions Inc. (the “Company”) entered into a First Amendment (the “Waiver Amendment”) to the Consent, Limited Waiver, and Third Amendment to the Amended and Restated Credit Agreement dated February 14, 2023 (the “Credit Agreement Amendment”) among the Company, as borrower, certain subsidiaries of the Company, as guarantors, Wells Fargo Bank, National Association, as administrative agent (in such capacity, the “Administrative Agent”), and certain lenders party thereto.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1367644/000136764423000082/0001367644-23-000082-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.